相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
X. Bai et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
X. Bai et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Ursolic Acid Exhibits Potent Anticancer Effects in Human Metastatic Melanoma Cancer Cells (SK-MEL-24) via Apoptosis Induction, Inhibition of Cell Migration and Invasion, Cell Cycle Arrest, and Inhibition of Mitogen-Activated Protein Kinase (MAPK)/ERK Signaling Pathway
Pengcheng Liu et al.
MEDICAL SCIENCE MONITOR (2019)
Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance
Aaron Goldman et al.
SCIENCE SIGNALING (2019)
Chondroprotective effects of 4-methylumbelliferone and hyaluronan synthase-2 overexpression involve changes in chondrocyte energy metabolism
Kenya Terabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications
Tiziana Tataranni et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Selective in vitro anti-melanoma activity of ursolic and oleanolic acids
Camelia Oprean et al.
TOXICOLOGY MECHANISMS AND METHODS (2018)
Selective in vitro anti-melanoma activity of ursolic and oleanolic acids
Camelia Oprean et al.
TOXICOLOGY MECHANISMS AND METHODS (2018)
Editorial: Redox and Metabolic Circuits in Cancer
Salvatore Rizza et al.
FRONTIERS IN ONCOLOGY (2018)
Effects of ursolic and oleanolic on SK-MEL-2 melanoma cells: In vitro and in vivo assays
Angela Caunii et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines
Christopher R. Bodle et al.
JOURNAL OF NATURAL PRODUCTS (2017)
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
Giulia Cesi et al.
MOLECULAR CANCER (2017)
Inhibition of retinoic acid receptor β signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells
Cecilie Abildgaard et al.
ONCOTARGET (2017)
Long-term stabilization of metastatic melanoma with sodium dichloroacetate
Akbar Khan et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells
Anna Lewinska et al.
APOPTOSIS (2017)
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms
Mei Peng et al.
CANCER TREATMENT REVIEWS (2017)
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Gao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy
Chia-Chieh Wu et al.
MOLECULES (2016)
Metformin: An anti-diabetic drug to fight cancer
Marie Daugan et al.
PHARMACOLOGICAL RESEARCH (2016)
Repurposing old drugs to chemoprevention: the case of metformin
Brandy M. Heckman-Stoddard et al.
SEMINARS IN ONCOLOGY (2016)
Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer
Eri Yoshida et al.
ONCOLOGY LETTERS (2016)
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
Quincy Siu-Chung Chu et al.
INVESTIGATIONAL NEW DRUGS (2015)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob et al.
LANCET ONCOLOGY (2015)
Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition
Jie Zhang et al.
ONCOLOGY REPORTS (2015)
Molecular drivers of cellular metabolic reprogramming in melanoma
Cecilie Abildgaard et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials
Ruiqin Mai et al.
ONCOTARGET (2015)
4-Methylumbe liferone treatment and hyaluronan innibition as a therapeutic strategy in nflammation, autoimmunity, and cancer
Nadine Nagy et al.
FRONTIERS IN IMMUNOLOGY (2015)
Ursolic acid induced apoptotic cell death following activation of caspases in isolated human melanoma cells
Mahmoud Mahmoudi et al.
CELL BIOLOGY INTERNATIONAL (2015)
Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells
Eun-Sook Kim et al.
ONCOLOGY LETTERS (2015)
Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
Rizwan Haq et al.
CLINICAL CANCER RESEARCH (2014)
Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition
Cecilie Abildgaard et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Cutaneous melanoma
Alexander M. M. Eggermont et al.
LANCET (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma
Meike Schneider et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility
Claus Christensen et al.
NATURE COMMUNICATIONS (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
Tiffany J. Parmenter et al.
CANCER DISCOVERY (2014)
Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis
Jichuang Wang et al.
SCIENTIFIC REPORTS (2014)
Natural products as potential cancer therapy enhancers: A preclinical update
Abed Agbarya et al.
SAGE OPEN MEDICINE (2014)
PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress
Francisca Vazquez et al.
CANCER CELL (2013)
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Rizwan Haq et al.
CANCER CELL (2013)
Ursolic acid inhibits tumor angiogenesis and induces apoptosis through mitochondrial-dependent pathway in Ehrlich ascites carcinoma tumor
Sarita Saraswati et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2013)
Evaluation of toxicity and single-dose pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and patients with advanced solid tumors
Xian-Huo Wang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors
Zhongling Zhu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARβ Signaling
Christina Dahl et al.
MOLECULAR CANCER RESEARCH (2013)
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence
Joanna Kaplon et al.
NATURE (2013)
Metrics other than potency reveal systematic variation in responses to cancer drugs
Mohammad Fallahi-Sichani et al.
NATURE CHEMICAL BIOLOGY (2013)
Metabolic targets for cancer therapy
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene
Arnaldur Hall et al.
ONCOTARGET (2013)
Inactivation of the HIF-1α/PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants
Jerome Kluza et al.
CANCER RESEARCH (2012)
Terpenoids: natural products for cancer therapy
Min Huang et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice
Flavia Piccioni et al.
GLYCOBIOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Comparative Metabolic Flux Profiling of Melanoma Cell Lines BEYOND THE WARBURG EFFECT
David A. Scott et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
Franziska Niehr et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Terpenoids as potential chemopreventive and therapeutic agents in liver cancer
Roslin J. Thoppil et al.
WORLD JOURNAL OF HEPATOLOGY (2011)
4-Methylumbelliferone inhibits tumour cell growth and the activation of stromal hyaluronan synthesis by melanoma cell-derived factors
M. Edward et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Antitumor Activity of Hyaluronic Acid Synthesis Inhibitor 4-Methylumbelliferone in Prostate Cancer Cells
Vinata B. Lokeshwar et al.
CANCER RESEARCH (2010)
The European searchable tumour line database
James Robinson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)